A Phase II trial of Recce Pharmaceutical’s topical skin infection gel has ‘exceeded expectations’, with 93% of patients achieving the primary efficacy endpoint. The Australian company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback